title: [Survey of tumor necrosis factor inhibitors application in patients with rheumatoid arthritis in China].
abstract: OBJECTIVE
  To investigate the current status of tumor necrosis factor (TNF) inhibitors application in rheumatoid arthritis (RA) patients in China and to  analyze the related factors.
  
  
  METHODS
  A retrospective survey was conducted in 21 hospitals from different parts of China. The patients with RA were  randomly enrolled. Data of their social backgrounds, clinical conditions, usage and adverse effects of TNF inhibitors were collected. The costs of TNF  inhibitors and the indirect costs of the disease were calculated. A multivariate Logistic regression analysis was performed to analyze the factors related to  TNF inhibitors application.
  
  
  RESULTS
  In the study, 1 095 RA patients from July 2009 to November 2010 were enrolled, of whom 112 had received TNF  inhibitors, representing 10.2% of the total patients. The patients who received etanercept and infliximab were 7.4% (86/1 095) of the patients and 2.4% (26/1  095), respectively. There were 0.5% of the patients (5/1 095) who had received both of the TNF inhibitors. The patients who had accepted etanercept and  treatment duration for less than 3 months and 3-6 months accounted for 38.5% and 25.0% respectively, while those treated with Infliximab were 38.1%. Their  health assessment questionnaire (HAQ) scores were 1.1, 0.5 and 0.1, corresponding to treatment duration of infliximab for less than 3, 3-6 and 6-9 months  and those were 1.3, 1.0, 0.3 corresponding to treatment duration of etanercept, respectively. Infliximab costs were RMB 24 525.0, 69 300.0 and 96 800.0 Yuan  and etanercept costs were RMB 7 394.8, 9 158.6, 54 910.9 Yuan, respectively. Indirect costs for RA patients who accepted infliximab for less than 3, 3-6 and  6-9 months were RMB 365.6, 0 and 158.9 Yuan and those who accepted etanercept were RMB 2 158.4, 288.5 and 180.1 Yuan, respectively. Allergy and  infection were the main side-effects of etanercept and both happened in 3.5% of all the patients. Liver damage happened in 2.3% of all the patients, while  allergy and infection happened in 6.5% of all the patients who accepted infliximab. Logistic regression analysis showed that patients with higher education  experience increased the odds of entering the TNF inhibitors group (OR: 1.292, 95%CI: 1.132-1.473, P=0.000).
  
  
  CONCLUSIONS
  About one-tenth of RA  patients in China have accepted TNF inhibitors. Higher education experience is the key factor for using TNF inhibitors.
authors.affiliation: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Xiu-ru
authors.initials: XR
authors.lastname: Wang
authors.forename: Yin
authors.initials: Y
authors.lastname: Su
authors.forename: Yuan
authors.initials: Y
authors.lastname: An
authors.forename: Yun-shan
authors.initials: YS
authors.lastname: Zhou
authors.forename: Xiao-ying
authors.initials: XY
authors.lastname: Zhang
authors.forename: Tian-jiao
authors.initials: TJ
authors.lastname: Duan
authors.forename: Jia-xin
authors.initials: JX
authors.lastname: Zhu
authors.forename: Xiao-feng
authors.initials: XF
authors.lastname: Li
authors.forename: Cai-hong
authors.initials: CH
authors.lastname: Wang
authors.forename: Li-zhi
authors.initials: LZ
authors.lastname: Wang
authors.forename: Yong-fu
authors.initials: YF
authors.lastname: Wang
authors.forename: Rong
authors.initials: R
authors.lastname: Yang
authors.forename: Guo-chun
authors.initials: GC
authors.lastname: Wang
authors.forename: Xin
authors.initials: X
authors.lastname: Lu
authors.forename: Ping
authors.initials: P
authors.lastname: Zhu
authors.forename: Li-Na
authors.initials: LN
authors.lastname: Chen
authors.forename: Yi
authors.initials: Y
authors.lastname: Wang
authors.forename: Xiao-Yuan
authors.initials: XY
authors.lastname: Wang
authors.forename: Hong-Tao
authors.initials: HT
authors.lastname: Jin
authors.forename: Jin-Ting
authors.initials: JT
authors.lastname: Liu
authors.forename: Hai-Ying
authors.initials: HY
authors.lastname: Chen
authors.forename: Ping
authors.initials: P
authors.lastname: Wei
authors.forename: Jun-Xiang
authors.initials: JX
authors.lastname: Wang
authors.forename: Xiang-Yuan
authors.initials: XY
authors.lastname: Liu
authors.forename: Lin
authors.initials: L
authors.lastname: Sun
authors.forename: Liu-Fu
authors.initials: LF
authors.lastname: Cui
authors.forename: Rong
authors.initials: R
authors.lastname: Shu
authors.forename: Bai-lu
authors.initials: BL
authors.lastname: Liu
authors.forename: Zhuo-li
authors.initials: ZL
authors.lastname: Zhang
authors.forename: Guang-tao
authors.initials: GT
authors.lastname: Li
authors.forename: Zhen-bin
authors.initials: ZB
authors.lastname: Li
authors.forename: Jing
authors.initials: J
authors.lastname: Yang
authors.forename: Jun-fang
authors.initials: JF
authors.lastname: Li
authors.forename: Bin
authors.initials: B
authors.lastname: Jia
authors.forename: Feng-xiao
authors.initials: FX
authors.lastname: Zhang
authors.forename: Jie-mei
authors.initials: JM
authors.lastname: Tao
authors.forename: Jin-yng
authors.initials: JY
authors.lastname: Lin
authors.forename: Mei-qiu
authors.initials: MQ
authors.lastname: Wei
authors.forename: Xiao-min
authors.initials: XM
authors.lastname: Liu
authors.forename: Dan
authors.initials: D
authors.lastname: Ke
authors.forename: Shao-xian
authors.initials: SX
authors.lastname: Hu
authors.forename: Cong
authors.initials: C
authors.lastname: Ye
authors.forename: Shu-ling
authors.initials: SL
authors.lastname: Han
authors.forename: Xiu-yan
authors.initials: XY
authors.lastname: Yang
authors.forename: Hao
authors.initials: H
authors.lastname: Li
authors.forename: Ci-bo
authors.initials: CB
authors.lastname: Huang
authors.forename: Ming
authors.initials: M
authors.lastname: Gao
authors.forename: Pei
authors.initials: P
authors.lastname: Lai
authors.forename: Xing-fu
authors.initials: XF
authors.lastname: Li
authors.forename: Li-jun
authors.initials: LJ
authors.lastname: Song
authors.forename: Rong
authors.initials: R
authors.lastname: Mu
authors.forename: Zhan-guo
authors.initials: ZG
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000191:economics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics; D002681:China; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000191:economics / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000191:economics / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011306:Prescription Fees / Q000706:statistics & numerical data*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D000079424:Tumor Necrosis Factor Inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000079424:Tumor Necrosis Factor Inhibitors; D000069285:Infliximab; D000068800:Etanercept